GL Biochem (Shanghai): difference between revisions
Diff·revision 9 → 10·23:49, 16 Sep 2024
Difference between revision 9 and revision 10 of GL Biochem (Shanghai). 6 lines changed; the page grew by 1,072 bytes.
| Revision 9 — 21:18, 3 Sep 2024 SPPS_Sorrel (talk) rm the discount code added by an anonymous editor 5,325 bytes ±0 | Revision 10 — 23:49, 16 Sep 2024 ShortageShona (talk) label the reception tally as weak, self-selected evidence at this point of use 6,397 bytes +1,072 | ||
|---|---|---|---|
| 1 | {{Infobox organisation | 1 | {{Infobox organisation |
| 2 | | name = GL Biochem (Shanghai) Ltd. | 2 | | name = GL Biochem (Shanghai) Ltd. |
| + | 3 | | image = facility.svg | |
| + | 4 | | caption = Schematic synthesis and quality-control site. No image of this organisation's premises is available to this wiki. | |
| 3 | | Legal name = GL Biochem (Shanghai) Ltd. | 5 | | Legal name = GL Biochem (Shanghai) Ltd. |
| 4 | | Trading name = GL Biochem | 6 | | Trading name = GL Biochem |
| ⋮ | ⋮ | ||
| 30 | The organisation's described activity is [[Custom peptide synthesis|custom synthesis]] to specification and supply of protected amino acid derivatives and coupling reagents — the inputs to [[Solid-phase peptide synthesis|solid-phase synthesis]] rather than its retail output.{{r|selfpub}} | 32 | The organisation's described activity is [[Custom peptide synthesis|custom synthesis]] to specification and supply of protected amino acid derivatives and coupling reagents — the inputs to [[Solid-phase peptide synthesis|solid-phase synthesis]] rather than its retail output.{{r|selfpub}} |
| 31 | 33 | ||
| + | 34 | Purchaser reports reaching this wiki are consequently different in character from those for retail suppliers: they describe quotations, specification agreement, lead times measured in weeks, and certificates reporting purity, mass confirmation and amino acid analysis.{{r|reports}} Reported documentation has been consistently more complete than for retail suppliers, which is what a laboratory-supply market expects rather than a distinguishing achievement.{{r|usp1503}} | |
| + | 35 | ||
| 32 | == References == | 36 | == References == |
| 33 | {{reflist}} | 37 | {{reflist}} |
| 34 | <ref name="registry">National Enterprise Credit Information Publicity System (国家企业信用信息公示系统), company registration record, retrieved 2026. Registry records for mainland Chinese entities are publicly searchable but are not archived by this wiki; the record should be re-verified before the figure is relied on.</ref> | 38 | <ref name="registry">National Enterprise Credit Information Publicity System (国家企业信用信息公示系统), company registration record, retrieved 2026. Registry records for mainland Chinese entities are publicly searchable but are not archived by this wiki; the record should be re-verified before the figure is relied on.</ref> |
| 35 | <ref name="selfpub">Organisation's own published product and company documentation, retrieved 2026. Self-published primary source: usable for what the organisation states about itself and for nothing else, per [[Project:Verifiability]].</ref> | 39 | <ref name="selfpub">Organisation's own published product and company documentation, retrieved 2026. Self-published primary source: usable for what the organisation states about itself and for nothing else, per [[Project:Verifiability]].</ref> |
| + | 40 | <ref name="reports">Independent test reports submitted to PeptidePedia by purchasers, 2024–2026. Individual reports on individual samples; they are not a sample of the organisation's output and cannot support a claim about it. See [[Blind sampling]].</ref> | |
| 36 | <ref name="tally">PeptidePedia reception tally (self-reported submissions; '''weak evidence''' — see [[Project:Sourcing guidelines]]). Self-selected sample; period and count stated at each point of use.</ref> | 41 | <ref name="tally">PeptidePedia reception tally (self-reported submissions; '''weak evidence''' — see [[Project:Sourcing guidelines]]). Self-selected sample; period and count stated at each point of use.</ref> |
| + | 42 | <ref name="usp1503">United States Pharmacopeia, General Chapter <1503>, "Quality Attributes of Synthetic Peptide Drug Substances" (informational). USP–NF, current revision.</ref> | |
| 37 | <ref name="ruo">Research-use-only labelling practice; see [[Research use only]] for the legal and commercial function of the phrase.</ref> | 43 | <ref name="ruo">Research-use-only labelling practice; see [[Research use only]] for the legal and commercial function of the phrase.</ref> |
| 38 | <ref name="gmp">World Health Organization, ''Good Manufacturing Practices for Pharmaceutical Products: Main Principles'', WHO Technical Report Series. The general framework against which a GMP claim is assessed.</ref> | 44 | <ref name="gmp">World Health Organization, ''Good Manufacturing Practices for Pharmaceutical Products: Main Principles'', WHO Technical Report Series. The general framework against which a GMP claim is assessed.</ref> |